No Data
No Data
Mizuho Securities Maintains EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Maintains Target Price $30
Mizuho Securities analyst Graig Suvannavejh maintains $EyePoint Pharmaceuticals(EYPT.US)$ with a buy rating, and maintains the target price at $30.According to TipRanks data, the analyst has a success
Capital One Financial Maintains EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Maintains Target Price $35
Capital One Financial analyst Tim Chiang maintains $EyePoint Pharmaceuticals(EYPT.US)$ with a buy rating, and maintains the target price at $35.According to TipRanks data, the analyst has a success ra
EyePoint Pharmaceuticals(EYPT.US) Director Sells US$119.7K in Common Stock
$EyePoint Pharmaceuticals(EYPT.US)$ Director GUYER DAVID R sold 11,625 shares of common stock on Jun 3, 2024 at an average price of $10.2972 for a total value of $119.7K.Source: Announcement What is s
EyePoint Pharmaceuticals Is Maintained at Overweight by JP Morgan
EyePoint Pharmaceuticals Is Maintained at Overweight by JP Morgan
JPMorgan Adjusts EyePoint Pharmaceuticals Price Target to $32 From $35, Maintains Overweight Rating
EyePoint Pharmaceuticals (EYPT) has an average rating of Buy and price targets ranging from $28 to $68, according to analysts polled by Capital IQ.
Express News | EyePoint Pharmaceuticals Inc : JP Morgan Cuts Target Price to $32 From $35
No Data